4//SEC Filing
BYERS BLAKE 4
Accession 0000899243-18-018319
CIK 0001690585other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 4:25 PM ET
Size
10.7 KB
Accession
0000899243-18-018319
Insider Transaction Report
Form 4
BYERS BLAKE
Director
Transactions
- Conversion
Common Stock
2018-06-25+3,339,137→ 3,339,137 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2018-06-25−133,400→ 0 total(indirect: See Footnote)→ Common Stock (51,626 underlying) - Conversion
Series B Preferred Stock
2018-06-25−8,494,864→ 0 total(indirect: See Footnote)→ Common Stock (3,287,511 underlying)
Footnotes (2)
- [F1]The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.
- [F2]The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.
Documents
Issuer
Magenta Therapeutics, Inc.
CIK 0001690585
Entity typeother
Related Parties
1- filerCIK 0001741840
Filing Metadata
- Form type
- 4
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 4:25 PM ET
- Size
- 10.7 KB